Joshua Milner is the chief of the Laboratory of Allergic Diseases and the Genetics and Pathogenesis of Allergy Section within the National Institute of Allergy and Infectious Diseases at the NIH in Bethesda, MD. He graduated from MIT, received his MD from the Albert Einstein College of Medicine, trained in pediatrics at the Children's National Medical Center in Washington DC and in allergy and immunology at the NIAID in Bethesda, MD through the Pediatric Scientist Development Program fellowship mentored by Dr. William E. Paul. His laboratory conducts basic, translational and clinical research revolving around the identification and study of congenital syndromes which have allergy as a major phenotype, a set of disorders his group has termed Primary Atopic Disorders. These have included cold-urticaria-associated PLCG2-associated Antibody deficiency and Immune Dysregulation (PLAID), PGM3 Deficiency, Hereditary Alpha Tryptasemia Syndrome (HATs), CARD11-associated Atopy with Dominant Interference of NF-κB Signaling (CADINS) and others. His lab has identified and studied other immune dysregulatory disorders as well such as STAT3 gain of function mutations in multisystem autoimmunity and lymphoproliferation. The goal of identifying and studying these disorders is both to improve the diagnostic and therapeutic options for patients with such rare diseases, and to identify pathways and interventions fundamental to allergic disease in general. He is a recipient of the PhARF award for allergy research (Uppsala University, Sweden), the Gail and Ira Drukier Prize in Children's Health Research (Cornell University), and is an elected member of the American Society for Clinical Investigation and the Association of American Physicians.